Search

Your search keyword '"De Marchi, Federico"' showing total 48 results
Start Over Author "De Marchi, Federico" Publication Year Range Last 50 years
48 results on '"De Marchi, Federico"'

1. Unlocking Diversity of Fast-Switched Optical Data Center Networks with Unified Routing

Author

Li, Jialong, De Marchi, Federico, Lei, Yiming, Joshi, Raj, Chandrasekaran, Balakrishnan, and Xia, Yiting

Subjects
Computer Science - Networking and Internet Architecture
Abstract

Optical data center networks (DCNs) are emerging as a promising solution for cloud infrastructure in the post-Moore's Law era, particularly with the advent of 'fast-switched' optical architectures capable of circuit reconfiguration at microsecond or even nanosecond scales. However, frequent reconfiguration of optical circuits introduces a unique challenge: in-flight packets risk loss during these transitions, hindering the deployment of many mature optical hardware designs due to the lack of suitable routing solutions. In this paper, we present Unified Routing for Optical networks (URO), a general routing framework designed to support fast-switched optical DCNs across various hardware architectures. URO combines theoretical modeling of this novel routing problem with practical implementation on programmable switches, enabling precise, time-based packet transmission. Our prototype on Intel Tofino2 switches achieves a minimum circuit duration of 2us, ensuring end-to-end, loss-free application performance. Large-scale simulations using production DCN traffic validate URO's generality across different hardware configurations, demonstrating its effectiveness and efficient system resource utilization.

Published
2024

2. Lighthouse: An Open Research Framework for Optical Data Center Networks

Author

Lei, Yiming, De Marchi, Federico, Li, Jialong, Joshi, Raj, Chandrasekaran, Balakrishnan, and Xia, Yiting

Subjects
Computer Science - Networking and Internet Architecture
Abstract

Optical data center networks (DCNs) are emerging as a promising design for cloud infrastructure. However, existing optical DCN architectures operate as closed ecosystems, tying software solutions to specific optical hardware. We introduce Lighthouse, an open research framework that decouples software from hardware, allowing them to evolve independently. Central to Lighthouse is the time-flow table abstraction, serving as a common interface between optical hardware and software. We develop Lighthouse on programmable switches, achieving a minimum optical circuit duration of 2 {\mu}s, the shortest duration realized by commodity devices to date. We demonstrate Lighthouse's generality by implementing six optical architectures on an optical testbed and conducted extensive benchmarks on a 108-ToR setup, highlighting system efficiency. Additionally, we present case studies that identify potential research topics enabled by Lighthouse.

Published
2024

6. Models of Non-Well-Founded Sets via an Indexed Final Coalgebra Theorem

Author

Berg, Benno van den and De Marchi, Federico

Subjects
Mathematics - Logic, Mathematics - Category Theory, 03C62, 03G30, 18C50
Abstract

The paper uses the formalism of indexed categories to recover the proof of a standard final coalgebra theorem, thus showing existence of final coalgebras for a special class of functors on categories with finite limits and colimits. As an instance of this result, we build the final coalgebra for the powerclass functor, in the context of a Heyting pretopos with a class of small maps. This is then proved to provide a model for various non-well-founded set theories, depending on the chosen axiomatisation for the class of small maps.

Published
2005

7. Non-well-founded trees in categories

Author

Berg, Benno van den and de Marchi, Federico

Subjects
Mathematics - Category Theory, 18A15, 68Q55, 68Q65
Abstract

Non-well-founded trees are used in mathematics and computer science, for modelling non-well-founded sets, as well as non-terminating processes or infinite data-structures. Categorically, they arise as final coalgebras for polynomial endofunctors, which we call M-types. In order to reason about trees, we need the notion of path, which can be formalised in the internal logic of any locally cartesian closed pretopos with a natural number object. In such categories, we derive existence results about M-types, leading to stability of locally cartesian closed pretoposes with a natural number object and M-types under slicing, formation of coalgebras (for a cartesian comonad), and sheaves for an internal site., Comment: Submitted for publication

Published
2004

8. Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers

Author

De Marchi, Federico, Haley, Lisa, Fryer, Henderson, Ibrahim, Junaid, Beierl, Katie, Zheng, Gang, Gocke, Christopher D., Eshleman, James R., Belchis, Deborah, Illei, Peter, and Lin, Ming-Tseh

Subjects
Epidermal growth factors -- Health aspects, Protein kinases -- Health aspects, Gene mutation -- Health aspects, Cellular signal transduction -- Genetic aspects -- Health aspects, Lung cancer -- Diagnosis -- Genetic aspects, Non-small cell lung cancer, Tumors, Diagnostic equipment (Medical), Phospholipids, DNA, Mitogens, Genes, Criminal investigation, Crizotinib, Health
Abstract

Context.--Mutations within the same signature transduction pathway are redundant and, therefore, most are mutually exclusive. Laboratory errors, however, may introduce unexpected coexisting mutations. Objective.--To validate coexisting mutations within epidermal growth factor receptor (EGFR), mitogen-activated protein kinase, and phosphatidylinositol 3-kinase pathways. Design.--In this retrospective study for quality assessment of next-generation sequencing in a clinical diagnostics setting, coexisting mutations within EGFR, KRAS, NRAS, BRAF, AKT1, and PIK3CA genes were examined in 1208 non-small cell lung cancers. Results.--EGFR mutations did not coexist with BRAF mutations, neither kinase-activated nor kinase-impaired mutations. There was a low but similar incidence (3.3%5.1%) of PIK3CA mutations in BRAF-, EGFR-, and KRAS-mutated lung cancers and a rare incidence of coexisting KRAS and EGFR mutations detected in 1 of 1208 lung cancers (0.08%) or 1 of 226 EGFR-mutated lung cancers (0.4%). Coexisting BRAF p.V600E mutation was observed in 3 of 4 AKT1 p.E17K-mutated lung cancers. Mutational profiling of DNA reisolated from subareas with the same or different histomorphology, using an alternative assay, confirmed that coexisting mutations might present within the same (whole or subclonal) population or different populations and clarified that the so-called coexisting activating KRAS and BRAF mutations originally reported in a specimen were indeed present in separate lung nodules submitted in the same block. Conclusions.--The results supported that EGFR and BRAF mutations are early driver mutations in lung cancers. Guidelines from official organizations to establish standard operating procedures are warranted to validate unexpected coexisting mutations and, if clinically indicated, to determine their presence in the same or different tumor populations. doi: 10.5858/arpa.2017-0495-OA, Several therapeutic agents have been approved by the US Food and Drug Administration in the United States for targeted therapy of metastatic non-small cell lung cancers (NSCLCs). (1) These include [...]

Published
2019
Full Text
View/download PDF

11. Monads in coalgebra

Author

De Marchi, Federico

Subjects
512
Abstract

Universal algebra has long been regarded as a fundamental tool in studying semantics of programming languages. Within this paradigm, one can formulate statements regarding the correctness of a program by looking at the interpretations of the code in any model for the language.;While this provides a description of finite computations, other models have to be introduced in order to provide a semantics for recursion and infinite computations in general. This leads to a study of rational and infinite terms. Such terms arise by a dual construction to that of the finite ones. namely, while the latter form an initial algebra, the former are a final coalgebra.;For this reason, it is natural to approach the study of infinite terms by dualising the categorical model of universal algebra. This leads to various different constructions, which are worth of investigation. In this thesis we approach two of them. In one case, we introduce the notions of cosignature, coequation and comodel, in the spirit of the theory of coalgebraic specification. In the second we focus on the properties of monads which can model infinitary computations. Such monads we call guarded, and include, amongst others, the monads of finite terms, infinite terms, rational terms and term graphs. As a byproduct of identifying this notion, we can solve algebraic systems of equation, which are an abstract counterpart to the notion of a recursive program scheme.;Many guarded monads we encounter are obtained by collecting, in an appropriate sense, a suitable family of coagebras. These examples are all instances of a general theorem we present, which tells under which conditions we can define a monad by a colimit operation, and when such comonads are guarded.;The level of abstraction allowed by the use of the categorical formalism allows us to instantiate some of the results in different categories, obtaining a monadic semantics for rational and infinite parallel term rewriting.

Published
2003

12. On the Semantics of Coinductive Types in Martin-Löf Type Theory

Author

De Marchi, Federico, Hutchison, David, editor, Kanade, Takeo, editor, Kittler, Josef, editor, Kleinberg, Jon M., editor, Mattern, Friedemann, editor, Mitchell, John C., editor, Naor, Moni, editor, Nierstrasz, Oscar, editor, Pandu Rangan, C., editor, Steffen, Bernhard, editor, Sudan, Madhu, editor, Terzopoulos, Demetri, editor, Tygar, Dough, editor, Vardi, Moshe Y., editor, Weikum, Gerhard, editor, Fiadeiro, José Luiz, editor, Harman, Neil, editor, Roggenbach, Markus, editor, and Rutten, Jan, editor

Published
2005
Full Text
View/download PDF

13. Hop-On Hop-Off Routing

Author

Li, Jialong, primary, Lei, Yiming, additional, De Marchi, Federico, additional, Joshi, Raj, additional, Chandrasekaran, Balakrishnan, additional, and Xia, Yiting, additional

Published
2022
Full Text
View/download PDF

26. Graves' Disease Thyrotoxicosis and Propylthiouracil Related Agranulocytosis Successfully Treated with Therapeutic Plasma Exchange and G-CSF Followed by Total Thyroidectomy

Author

Candoni, Anna, De Marchi, Federico, Vescini, Fabio, Mauro, Sara, Rinaldi, Cristina, Piemonte, Marco, Rabassi, Nicholas, Dubbini, Maria Vittoria, and Fanin, Renato

Subjects
medicine.medical_specialty, Allergy, endocrine system, endocrine system diseases, medicine.medical_treatment, Graves' disease, Case Report, 030209 endocrinology & metabolism, 030204 cardiovascular system & hematology, Gastroenterology, Hyperthyroidism, 03 medical and health sciences, Hyperthyroidism, Agranulocytosis, 0302 clinical medicine, Pharmacotherapy, Internal medicine, medicine, Plasma exchange, Euthyroid, Total thyroidectomy, business.industry, lcsh:RC633-647.5, Thyroidectomy, Hematology, Plasmapheresis, lcsh:Diseases of the blood and blood-forming organs, medicine.disease, Infectious Diseases, Endocrinology, Agranulocytosis, Propylthiouracil, business, hormones, hormone substitutes, and hormone antagonists, medicine.drug
Abstract

Antithyroid drugs can be a rare cause of agranulocytosis (0.5% of treated patients). Suspension of these drugs is mandatory in these patients and may result in worsening hyperthyroidism. We report the case of a 27-year-old woman who is 3 months post-partum, breastfeeding, and suffering from Graves’ disease hyperthyroidism treated first with methimazole and then with propylthiouracil due to a methimazole allergy. She was admitted for urosepsis and agranulocytosis. The patient was diagnosed with propylthiouracil related agranulocytosis, diffuse toxic goiter, and thyro-gastric syndrome. Antithyroid drug therapy was stopped resulting in a worsening of thyrotoxicosis. Agranulocytosis was treated with 8 doses of G-CSF with full recovery. To rapidly restore euthyroidism and to perform a thyroidectomy, the patient received 6 plasmapheresis procedures, to clear thyroid hormones and anti-TSH receptor antibodies from the blood, resulting in a pre-surgical euthyroid state without antithyroid drugs. One year after thyroidectomy, the patient is well on thyroid hormone replacement therapy. Key Words: Plasmapheresis; Hyperthyroidism, Agranulocytosis; Propylthiouracil.

Published
2017

27. Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers

Author

De Marchi, Federico, primary, Haley, Lisa, additional, Fryer, Henderson, additional, Ibrahim, Junaid, additional, Beierl, Katie, additional, Zheng, Gang, additional, Gocke, Christopher D., additional, Eshleman, James R., additional, Belchis, Deborah, additional, Illei, Peter, additional, and Lin, Ming-Tseh, additional

Published
2018
Full Text
View/download PDF

28. Hedgehog/GLI1 activation leads to leukemic transformation of myelodysplastic syndrome in vivo and GLI1 inhibition results in antitumor activity

Author

Lau, Bonnie W., primary, Huh, Kyounghee, additional, Madero-Marroquin, Rafael, additional, De Marchi, Federico, additional, Lim, Yiting, additional, Wang, Qiuju, additional, Lobo, Francisco, additional, Marchionni, Luigi, additional, Smith, Douglas B., additional, DeZern, Amy, additional, Levis, Mark J., additional, Aplan, Peter D., additional, Matsui, William, additional, and Gondek, Lukasz P., additional

Published
2018
Full Text
View/download PDF

29. Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients

Author

Tiribelli, Mario, primary, Bonifacio, Massimiliano, additional, Binotto, Gianni, additional, Iurlo, Alessandra, additional, Cibien, Francesca, additional, Maino, Elena, additional, Guella, Anna, additional, Festini, Gianluca, additional, Minotto, Claudia, additional, De Biasi, Ercole, additional, De Marchi, Federico, additional, Scaffidi, Luigi, additional, Frison, Luca, additional, Bucelli, Cristina, additional, Medeot, Marta, additional, Calistri, Elisabetta, additional, Sancetta, Rosaria, additional, Stulle, Manuela, additional, Orofino, Nicola, additional, Krampera, Mauro, additional, Gherlinzoni, Filippo, additional, Semenzato, Gianpietro, additional, Pizzolo, Giovanni, additional, Ambrosetti, Achille, additional, and Fanin, Renato, additional

Published
2018
Full Text
View/download PDF

30. Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis

Author

Palandri, Francesca, primary, Palumbo, Giuseppe Alberto, additional, Bonifacio, Massimiliano, additional, Tiribelli, Mario, additional, Benevolo, Giulia, additional, Martino, Bruno, additional, Abruzzese, Elisabetta, additional, D’Adda, Mariella, additional, Polverelli, Nicola, additional, Bergamaschi, Micaela, additional, Tieghi, Alessia, additional, Cavazzini, Francesco, additional, Ibatici, Adalberto, additional, Crugnola, Monica, additional, Bosi, Costanza, additional, Latagliata, Roberto, additional, Di Veroli, Ambra, additional, Scaffidi, Luigi, additional, de Marchi, Federico, additional, Cerqui, Elisa, additional, Anaclerico, Barbara, additional, De Matteis, Giovanna, additional, Spinsanti, Marco, additional, Sabattini, Elena, additional, Catani, Lucia, additional, Aversa, Franco, additional, Di Raimondo, Francesco, additional, Vitolo, Umberto, additional, Lemoli, Roberto Massimo, additional, Fanin, Renato, additional, Merli, Francesco, additional, Russo, Domenico, additional, Cuneo, Antonio, additional, Bacchi Reggiani, Maria Letizia, additional, Cavo, Michele, additional, Vianelli, Nicola, additional, and Breccia, Massimo, additional

Published
2017
Full Text
View/download PDF

31. Clinical mutational profiling of 1006 lung cancers by next generation sequencing

Author

Illei, Peter B., primary, Belchis, Deborah, additional, Tseng, Li-Hui, additional, Nguyen, Doreen, additional, De Marchi, Federico, additional, Haley, Lisa, additional, Riel, Stacy, additional, Beierl, Katie, additional, Zheng, Gang, additional, Brahmer, Julie R., additional, Askin, Frederic B., additional, Gocke, Christopher D., additional, Eshleman, James R., additional, Forde, Patrick M., additional, and Lin, Ming-Tseh, additional

Published
2017
Full Text
View/download PDF

32. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia

Author

Candoni, Anna, primary, De Marchi, Federico, additional, Zanini, Francesca, additional, Zannier, Maria Elena, additional, Simeone, Erica, additional, Toffoletti, Eleonora, additional, Chiarvesio, Alexsia, additional, Cerno, Michela, additional, Filì, Carla, additional, Patriarca, Francesca, additional, and Fanin, Renato, additional

Published
2017
Full Text
View/download PDF

34. Similar Efficacy of Dasatinib and Nilotinib As Second-Line Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Failing Imatinib: A Retrospective, Real-Life Study

Author

Tiribelli, Mario, primary, Bonifacio, Massimiliano, additional, Binotto, Gianni, additional, Iurlo, Alessandra, additional, Cibien, Francesca, additional, Maino, Elena, additional, Guella, Anna, additional, Festini, Gianluca, additional, Minotto, Claudia, additional, De Biasi, Ercole, additional, De Marchi, Federico, additional, Scaffidi, Luigi, additional, Frison, Luca, additional, Bucelli, Cristina, additional, Medeot, Marta, additional, Calistri, Elisabetta, additional, Krampera, Mauro, additional, Gherlinzoni, Filippo, additional, Semenzato, Gianpietro, additional, Ambrosetti, Achille, additional, Pizzolo, Giovanni, additional, and Fanin, Renato, additional

Published
2016
Full Text
View/download PDF

35. Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis

Author

Palandri, Francesca, primary, Palumbo, Giuseppe A., additional, Bonifacio, Massimiliano, additional, Tiribelli, Mario, additional, Benevolo, Giulia, additional, Martino, Bruno, additional, Abruzzese, Elisabetta, additional, D'Adda, Mariella, additional, Polverelli, Nicola, additional, Bergamaschi, Micaela, additional, Tieghi, Alessia, additional, Cavazzini, Francesco, additional, Ibatici, Adalberto, additional, Crugnola, Monica, additional, Bosi, Costanza, additional, Latagliata, Roberto, additional, Di Veroli, Ambra, additional, Scaffidi, Luigi, additional, De Marchi, Federico, additional, Cerqui, Elisa, additional, Anaclerico, Barbara, additional, Di Raimondo, Francesco, additional, Vitolo, Umberto, additional, Lemoli, Roberto M, additional, Fanin, Renato, additional, Merli, Francesco, additional, Russo, Domenico, additional, Cuneo, Antonio, additional, Cavo, Michele, additional, Vianelli, Nicola, additional, and Breccia, Massimo, additional

Published
2016
Full Text
View/download PDF

37. Predictive Factors of Stable Deep Molecular Response in Chronic Myeloid Leukemia Patients Treated with Imatinib Standard Dose: A Study from the Gruppo Triveneto LMC

Author

Bonifacio, Massimiliano, primary, Scaffidi, Luigi, additional, Binotto, Gianni, additional, De Marchi, Federico, additional, Maino, Elena, additional, Calistri, Elisabetta, additional, Bonalumi, Angela, additional, Frison, Luca, additional, Marin, Luciana, additional, Medeot, Marta, additional, De Matteis, Giovanna, additional, Fanin, Renato, additional, Semenzato, Gianpietro, additional, Ambrosetti, Achille, additional, and Tiribelli, Mario, additional

Published
2015
Full Text
View/download PDF

45. Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis

Author

Micaela Bergamaschi, Alessia Tieghi, Bruno Martino, Monica Crugnola, Massimo Breccia, Adalberto Ibatici, Nicola Vianelli, Massimiliano Bonifacio, Giulia Benevolo, Mariella D'Adda, Barbara Anaclerico, Michele Cavo, Marco Spinsanti, Elisa Cerqui, Roberto Latagliata, Francesco Cavazzini, Elisabetta Abruzzese, Giuseppe A. Palumbo, Federico De Marchi, Giovanna De Matteis, Costanza Bosi, Roberto M. Lemoli, Franco Aversa, Elena Sabattini, Ambra Di Veroli, Francesco Di Raimondo, Renato Fanin, Luigi Scaffidi, Maria Letizia Bacchi Reggiani, Antonio Cuneo, Domenico Russo, Mario Tiribelli, Lucia Catani, Francesca Palandri, Umberto Vitolo, Nicola Polverelli, Francesco Merli, Palandri, Francesca, Palumbo, Giuseppe Alberto, Bonifacio, Massimiliano, Tiribelli, Mario, Benevolo, Giulia, Martino, Bruno, Abruzzese, Elisabetta, D'Adda, Mariella, Polverelli, Nicola, Bergamaschi, Micaela, Tieghi, Alessia, Cavazzini, Francesco, Ibatici, Adalberto, Crugnola, Monica, Bosi, Costanza, Latagliata, Roberto, Di Veroli, Ambra, Scaffidi, Luigi, de Marchi, Federico, Cerqui, Elisa, Anaclerico, Barbara, De Matteis, Giovanna, Spinsanti, Marco, Sabattini, Elena, Catani, Lucia, Aversa, Franco, Di Raimondo, Francesco, Vitolo, Umberto, Lemoli, Roberto Massimo, Fanin, Renato, Merli, Francesco, Russo, Domenico, Cuneo, Antonio, Bacchi Reggiani, Maria Letizia, Cavo, Michele, Vianelli, Nicola, and Breccia, Massimo

Subjects
medicine.medical_specialty, Ruxolitinib, Bone marrow transplant, Socio-culturale, Myelofibrosis, Clinical biochemistry, predictive factor, 03 medical and health sciences, 0302 clinical medicine, Disease severity, myelofibrosi, Internal medicine, medicine, myelofibrosis, predictive factors, response, ruxolitinib, splenomegaly, Hematology, business.industry, Response, University hospital, medicine.disease, Transplantation, Oncology, 030220 oncology & carcinogenesis, Splenomegaly, Predictive factors, Clinical Research Paper, business, 030215 immunology, medicine.drug
Abstract

// Francesca Palandri 1 , Giuseppe Alberto Palumbo 2 , Massimiliano Bonifacio 3 , Mario Tiribelli 4 , Giulia Benevolo 5 , Bruno Martino 6 , Elisabetta Abruzzese 7 , Mariella D’Adda 8 , Nicola Polverelli 9 , Micaela Bergamaschi 10 , Alessia Tieghi 11 , Francesco Cavazzini 12 , Adalberto Ibatici 13 , Monica Crugnola 14 , Costanza Bosi 15 , Roberto Latagliata 16 , Ambra Di Veroli 17 , Luigi Scaffidi 3 , Federico de Marchi 4 , Elisa Cerqui 8 , Barbara Anaclerico 18 , Giovanna De Matteis 19 , Marco Spinsanti 1 , Elena Sabattini 1 , Lucia Catani 1 , Franco Aversa 14 , Francesco Di Raimondo 2 , Umberto Vitolo 5 , Roberto Massimo Lemoli 10 , Renato Fanin 4 , Francesco Merli 11 , Domenico Russo 9 , Antonio Cuneo 12 , Maria Letizia Bacchi Reggiani 20 , Michele Cavo 1 , Nicola Vianelli 1 and Massimo Breccia 16 1 Institute of Hematology “L. and A. Seragnoli”, Sant'Orsola-Malpighi University Hospital, Bologna, Italy 2 Division of Hematology, AOU 'Policlinico-V.Emanuele', Catania, Italy 3 Department of Hematology, University of Verona, Verona, Italy 4 Division of Hematology and BMT, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy 5 Division of Hematology, Citta della Salute e della Scienza Hospital, Torino, Italy 6 Division of Hematology, Azienda Ospedaliera 'Bianchi Melacrino Morelli', Reggio Calabria, Italy 7 Division of Hematology, Ospedale S. Eugenio, Roma, Italy 8 Division of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy 9 Unit of Blood Diseases and Stem Cell Transplantation, ASST Spedali Civili di Brescia, Brescia, Italy 10 Division of Hematology, IRCCS AOU San Martino-IST, Genova, Italy 11 Department of Hematology, A.O. Arcispedale Santa Maria Nuova – IRCCS, Reggio Emilia, Italy 12 Division of Hematology, University of Ferrara, Ferrara, Italy 13 Division of Hematology and Bone Marrow Transplant, IRCCS San Martino-IST, Genova, Italy 14 Division of Hematology, AOU of Parma, Parma, Italy 15 Department of Hematology and Bone Marrow Transplantation, A.O. of Piacenza, Italy 16 Division of Cellular Biotechnologies and Hematology, University Sapienza, Roma, Italy 17 Division of Hematology, Policlinico Tor Vergata, Roma, Italy 18 Division of Hematology, Ospedale S. Giovanni, Roma, Italy 19 Department of Life and Reproduction Sciences, Section of Clinical Biochemistry, University of Verona, Verona, Italy 20 Division of Cardiology, University of Bologna, Bologna, Italy Correspondence to: Francesca Palandri, email: francesca.palandri@unibo.it Keywords: myelofibrosis, splenomegaly, response, ruxolitinib, predictive factors Received: March 29, 2017 Accepted: May 15, 2017 Published: June 27, 2017 ABSTRACT In patients with Myelofibrosis (MF) treated with ruxolitinib (RUX), the response is unpredictable at therapy start. We retrospectively evaluated the impact of clinical/laboratory factors on responses in 408 patients treated with RUX according to prescribing obligations in 18 Italian Hematology Centers. At 6 months, 114 out of 327 (34.9%) evaluable patients achieved a spleen response. By multivariable Cox proportional hazard regression model, pre-treatment factors negatively correlating with spleen response were: high/intermediate-2 IPSS risk ( p =0.024), large splenomegaly ( p =0.017), transfusion dependency ( p =0.022), platelet count 2 years ( p =0.048). Also, patients treated with higher (≥10 mg BID) average RUX doses in the first 12 weeks achieved higher response rates ( p =0.019). After adjustment for IPSS risk, patients in spleen response at 6 months showed only a trend for better survival compared to non-responders. At 6 months, symptoms response was achieved by 85.5% of 344 evaluable patients; only a higher (>20) Total Symptom Score significantly correlated with lower probability of response ( p

Published
2017

46. First use of a scoring balloon to perform Oddi sphincteroplasty for biliary stones.

Author

Coppola A, Piacentino F, Macchi E, Marchi G, Ierardi AM, Carrafiello G, and Fontana F

Abstract

Balloon sphincteroplasty is a well-known procedure for the treatment of biliary stones. Scoring balloons are characterized by rigid tangential elements that provide focal force, achieving a greater pressure than normal balloons. We report the first (to our knowledge) use of a scoring balloon to perform sphincteroplasty in 4 cases of elderly people presenting with symptomatic choledocholithiasis. In all cases we achieved complete common bile duct clearing with good symptom relief. No procedural complications were observed., Competing Interests: Conflict of Interest: None

Published
2019
Full Text
View/download PDF

47. Graves' Disease Thyrotoxicosis and Propylthiouracil Related Agranulocytosis Successfully Treated with Therapeutic Plasma Exchange and G-CSF Followed by Total Thyroidectomy.

Author

Candoni A, De Marchi F, Vescini F, Mauro S, Rinaldi C, Piemonte M, Rabassi N, Dubbini MV, and Fanin R

Abstract

Antithyroid drugs can be a rare cause of agranulocytosis (0.5% of treated patients). Suspension of these drugs is mandatory in these patients and may result in worsening hyperthyroidism. We report the case of a 27-year-old woman who is 3 months post-partum, breastfeeding, and suffering with Graves' disease hyperthyroidism treated first with methimazole and then with propylthiouracil due to a methimazole allergy. She was admitted for urosepsis and agranulocytosis. The patient was diagnosed with propylthiouracil related agranulocytosis, diffuse toxic goiter and thyro-gastric syndrome. Antithyroid drug therapy was stopped resulting in a worsening of thyrotoxicosis. Agranulocytosis was treated with 8 doses of G-CSF with full recovery. To rapidly restore euthyroidism and to perform a thyroidectomy, the patient received 6 therapeutic plasma exchange (TPE) procedures, to clear thyroid hormones and anti-TSH receptor antibodies from blood, resulting in a pre-surgical euthyroid state without antithyroid drug therapy. Two years after thyroidectomy, the patient is well under thyroid hormone replacement therapy with a normal granulocyte count., Competing Interests: Competing interests: The authors have declared that no competing interests exist.

Published
2017
Full Text
View/download PDF

48. Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.

Author

Bonifacio M, Binotto G, Maino E, Calistri E, Marin L, Scaffidi L, Frison L, De Marchi F, Krampera M, Semenzato G, Fanin R, Ambrosetti A, and Tiribelli M

Subjects
Chromosome Aberrations, Fusion Proteins, bcr-abl genetics, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive mortality, Retrospective Studies, Time Factors, Treatment Outcome, Antineoplastic Agents therapeutic use, Imatinib Mesylate therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Protein Kinase Inhibitors therapeutic use
Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results